Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Biomarkers | Research article

Meta-analysis of Osteopontin splice variants in cancer

Authors: Yu An, Gulimirerouzi Fnu, Changchun Xie, Georg F. Weber

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

The cytokine Osteopontin is a mediator of tumor progression and cancer metastasis. In 2006, we reported that (in addition to the full-length form -a) splice variants of Osteopontin (forms -b and -c) are produced selectively by transformed cells. Through June 2021, 36 PubMed-indexed journal articles have studied Osteopontin splice variants in various cancer patients.

Methods

Applying a categorical approach previously developed by us, here we conduct a meta-analysis of the pertinent literature. We supplement this with evaluation of the relevant entries in the TSVdb database, which focusses on splice variant expression, thus including the additional variants -4 and -5. The analysis covers 5886 patients across 15 tumors from the literature and 10,446 patients across 33 tumors from TSVdb.

Results

The database yields positive results more frequently than the categorical meta-analysis. The two sources are in agreement on the elevation of OPN-a, OPN-b, and OPN-c in lung cancer and the elevation of OPN-c in breast cancer as compared to healthy tissue. Specific splice variants are associated with grade, stage, or patient survival pertaining to various cancers.

Conclusions

There are cases of persisting discrepancies, which require further investigation to clarify the Osteopontin splice variant utilization, so that their diagnostic, prognostic and potentially predictive potential can be brought to fruition.
Appendix
Available only for authorised users
Literature
1.
2.
Weber GF, Lett GS, Haubein NC. Categorical meta-analysis of Osteopontin as a clinical cancer marker. Oncol Rep. 2011;25(2):433–41.PubMedCrossRef
3.
Ashkar S, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 2000;287(5454):860–4.PubMedCrossRef
4.
Weber GF, Ashkar S. Stress response genes: the genes that make cancer metastasize. J Mol Med (Berl). 2000;78(8):404–8.PubMedCrossRef
5.
6.
Fish L, et al. A prometastatic splicing program regulated by SNRPA1 interactions with structured RNA elements. Science. 2021;372(6543).
7.
Briones-Orta MA, et al. Osteopontin splice variants and polymorphisms in cancer progression and prognosis. Biochim Biophys Acta Rev Cancer. 2017;1868(1):93-108A.PubMedCrossRef
8.
Mirza M, et al. Osteopontin-c is a selective marker of breast cancer. Int J Cancer. 2008;122(4):889–97.PubMedCrossRef
9.
Shen H, Weber GF. The osteopontin-c splice junction is important for anchorage-independent growth. Mol Carcinog. 2014;53(6):480–7.PubMedCrossRef
10.
He B, Mirza M, Weber GF. An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene. 2006;25(15):2192–202.PubMedCrossRef
11.
Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1–48.CrossRef
12.
Agresti A. An Introduction to Categorical Data Analysis. 2nd ed. Hoboken. NJ: John Wiley and Sons; 2007.CrossRef
13.
14.
Hanauer DA, et al. Bioinformatics approaches in the study of cancer. Curr Mol Med. 2007;7(1):133–41.PubMedCrossRef
15.
16.
17.
18.
Ortiz-Martinez F, et al. Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence. Hum Pathol. 2014;45(3):504–12.PubMedCrossRef
19.
Guttler A, et al. Osteopontin and splice variant expression level in human malignant glioma: radiobiologic effects and prognosis after radiotherapy. Radiother Oncol. 2013;108(3):535–40.PubMedCrossRef
20.
Takafuji V, et al. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene. 2007;26(44):6361–71.PubMedCrossRef
21.
22.
Wu J, et al. Identification and quantification of osteopontin splice variants in the plasma of lung cancer patients using immunoaffinity capture and targeted mass spectrometry. Biomarkers. 2012;17(2):125–33.PubMedCrossRef
23.
Zhao B, et al. Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer. J Cancer Res Clin Oncol. 2011;137(7):1061–70.PubMedCrossRef
24.
Sullivan J, et al. Expression of a prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma. Surgery. 2009;146(2):232–40.PubMedCrossRef
25.
Sullivan J, et al. Expression and regulation of nicotine receptor and osteopontin isoforms in human pancreatic ductal adenocarcinoma. Histol Histopathol. 2011;26(7):893–904.PubMed
26.
Ferreira LB, et al. OPNa Overexpression Is Associated with Matrix Calcification in Thyroid Cancer Cell Lines. Int J Mol Sci. 2018;19(10).
27.
Lin J, et al. Osteopontin (OPN/SPP1) isoforms collectively enhance tumor cell invasion and dissemination in esophageal adenocarcinoma. Oncotarget. 2015;6(26):22239–57.PubMedPubMedCentralCrossRef
28.
Kijewska M, et al. The embryonic type of SPP1 transcriptional regulation is re-activated in glioblastoma. Oncotarget. 2017;8(10):16340–55.PubMedCrossRef
29.
30.
Pang H, et al. Prognostic values of osteopontin-c, E-cadherin and beta-catenin in breast cancer. Cancer Epidemiol. 2013;37(6):985–92.PubMedCrossRef
31.
Patani N, Jiang W, Mokbel K. Osteopontin C mRNA expression is associated with a poor clinical outcome in human breast cancer. Int J Cancer. 2008;122(11):2646.PubMedCrossRef
32.
Patani N, et al. Osteopontin expression profiles predict pathological and clinical outcome in breast cancer. Anticancer Res. 2008;28(6B):4105–10.PubMed
33.
Sun X, et al. Expression of osteopontin splice variant and its clinical significance in gastric cancer. Zhonghua Zhong Liu Za Zhi. 2015;37(6):427–30.PubMed
34.
Ivanov SV, et al. Tumorigenic properties of alternative osteopontin isoforms in mesothelioma. Biochem Biophys Res Commun. 2009;382(3):514–8.PubMedCrossRef
35.
Siddiqui AA, et al. Osteopontin splice variant as a potential marker for metastatic disease in pancreatic adenocarcinoma. J Gastroenterol Hepatol. 2014;29(6):1321–7.PubMedPubMedCentralCrossRef
36.
37.
Huang J, et al. Enhanced osteopontin splicing regulated by RUNX2 is HDAC-dependent and induces invasive phenotypes in NSCLC cells. Cancer Cell Int. 2019;19:306.PubMedPubMedCentralCrossRef
38.
Chang S, et al. Epigenetic regulation of osteopontin splicing isoform c defines its role as a microenvironmental factor to promote the survival of colon cancer cells from 5-FU treatment. Cancer Cell Int. 2020;20:452.PubMedPubMedCentralCrossRef
39.
Zhang MX, et al. Overexpressed ostepontin-c as a potential biomarker for esophageal squamous cell carcinoma. Asian Pac J Cancer Prev. 2013;14(12):7315–9.PubMedCrossRef
40.
Tang X, et al. Osteopontin splice variants differentially exert clinicopathological features and biological functions in gastric cancer. Int J Biol Sci. 2013;9(1):55–66.PubMedCrossRef
41.
Sarosiek K, et al. Osteopontin (OPN) isoforms, diabetes, obesity, and cancer; what is one got to do with the other? a new role for OPN. J Gastrointest Surg. 2015;19(4):639–50.PubMedCrossRef
42.
Sun J, et al. Osteopontin splice variants expressed by breast tumors regulate monocyte activation via MCP-1 and TGF-beta1. Cell Mol Immunol. 2013;10(2):176–82.PubMedPubMedCentralCrossRef
43.
Silva GR, et al. Osteopontin-4 and Osteopontin-5 splice variants are expressed in several tumor cell lines. Mol Biol Rep. 2020;47(10):8339–45.PubMedCrossRef
44.
Bastos A, et al. Osteopontin and their roles in hematological malignancies: splice variants on the new avenues. Cancer Lett. 2017;408:138–43.PubMedCrossRef
45.
Mirzaei A, et al. OPN b and c isoforms doubtless veto anti-angiogenesis effects of curcumin in combination with conventional AML regiment. Asian Pac J Cancer Prev. 2017;18(9):2591–9.PubMedPubMedCentral
46.
Santoro JC, et al. Reinforcing osteopontin as a marker of central nervous system relapse in paediatric B-cell acute lymphoblastic leukaemia: SPP1 splice variant 3 in the spotlight. Br J Haematol. 2019;186(4):e88–91.PubMedCrossRef
47.
Marques DS, et al. Osteopontin-c isoform levels are associated with SR and hnRNP differential expression in ovarian cancer cell lines. Tumour Biol. 2017;39(9):1010428317725442.PubMedCrossRef
48.
Nakamura KD, et al. Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells. Tumour Biol. 2016;37(2):2655–63.PubMedCrossRef
49.
Tilli TM, Ferreira LB, Gimba ER. Osteopontin-c mediates the upregulation of androgen responsive genes in LNCaP cells through PI3K/Akt and androgen receptor signaling. Oncol Lett. 2015;9(4):1845–50.PubMedPubMedCentralCrossRef
50.
Tilli TM, et al. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells. Prostate. 2012;72(15):1688–99.PubMedCrossRef
51.
Boguslawska J, et al. microRNAs target SRSF7 splicing factor to modulate the expression of osteopontin splice variants in renal cancer cells. Gene. 2016;595(2):142–9.PubMedCrossRef
52.
Brum MCM, et al. Osteopontinc isoform inhibition modulates ovarian cancer cell cisplatin resistance, viability and plasticity. Oncol Rep. 2021;45(2):652–64.PubMedCrossRef
53.
Huang J, et al. Osteopontin isoform c promotes the survival of cisplatin-treated NSCLC cells involving NFATc2-mediated suppression on calcium-induced ROS levels. BMC Cancer. 2021;21(1):750.PubMedPubMedCentralCrossRef
Metadata
Title
Meta-analysis of Osteopontin splice variants in cancer
Authors
Yu An
Gulimirerouzi Fnu
Changchun Xie
Georg F. Weber
Publication date
01-12-2023
Publisher
BioMed Central
Keyword
Biomarkers
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10854-x

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

3D-based strain analysis and cardiotoxicity detection in cancer patients received chemotherapy

Research

SUV39H1 is a novel biomarker targeting oxidative phosphorylation in hepatitis B virus-associated hepatocellular carcinoma

Research

Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma

Research

The epidemiology of multiple primary cancers in Belgium (2004–2017): Incidence, proportion, risk, stage and impact on relative survival estimates

Research

Identification of ZBTB4 as an immunological biomarker that can inhibit the proliferation and invasion of pancreatic cancer

Research

Prognostic value of CYFRA 21 − 1 and Ki67 in advanced NSCLC patients with wild-type EGFR
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits